'The Exclusion of Older Persons From Vaccine & Treatment Trials For Coronavirus,' JAMA Network

[appalachiablue]

- 'The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019—Missing the Target.' Benjamin K. I. Helfand, MSc1,2; Margaret Webb, BA3; Sarah L. Gartaganis, MSW, MPH3...Sept. 28, 2020.

Older adults are at greatest risk of severe disease and death due to coronavirus disease 2019 (COVID-19). Globally, persons older than 65 years comprise 9% of the population,1 yet account for 30% to 40% of cases and more than 80% of deaths.2 Unfortunately, there is a long history of exclusion of older adults from clinical trials. In response, the National Institutes of Health instituted the Inclusion Across the Lifespan policy, requiring the inclusion of older adults in clinical trials.3 Thus, we reviewed all COVID-19 treatment and vaccine trials on http://www.clinicaltrials.gov to evaluate their risk for exclusion of older adults (≥65 years).

Methods: Details of our approach, methods, and description of included clinical trials are shown in the eMethods in the Supplement.

Each of the 847 clinical trials was abstracted by at least 1 trained research associate, with reliability checks of all ratings. Age exclusions were identified by viewing all of the eligibility and exclusionary criteria. Specific age exclusions were classified into 5-year categories from ages 55 to 80 years; our focus was on exclusion of the 65 to 80 years age group most affected by COVID-19. Informed consent was waived because all data were deidentified and came from previously published studies.

Results: Table 1 identifies clinical trials by treatment with an exclusion by age. We found large variability in the age exclusions. Among the 847 trials, 195 (23%) included an age cut-off. Table 2 displays indirect age-related exclusions preferentially affecting older adults; each trial could have multiple exclusions. The most common age-related exclusion was compliance concerns (213 trials), and 129 of these were related to consent. Next, were broad nonspecified exclusions, specific comorbidities, requirement of technology, and other reasons. A total of 366 (43%) trials had any exclusions, of which 252 (30%) did not have an age-based exclusion. Combining the results of age-based exclusions (Table 1) and exclusions preferentially affecting older adults (Table 2), 447 (53%) trials were considered high risk for excluding older adults.

In 232 phase 3 clinical trials, 38 (16%) included age cut-offs and 77 (33%) had exclusions preferentially affecting older adults; thus, 115 (50%) were considered high risk for excluding older adults. Of 18 vaccine trials, 11 (61%) included age cut-offs, and the remaining 7 had broad nonspecified exclusions; thus, 100% were considered high risk for excluding older adults.

Discussion: Our findings indicate that older adults are likely to be excluded from more than 50% of COVID-19 clinical trials and 100% of vaccine trials. Such exclusion will limit the ability to evaluate the efficacy, dosage, and adverse effects of the intended treatments. We acknowledge that some exclusions for severe or uncontrolled comorbidities will be essential to protect the health and safety of older adults. However, caution must be taken to avoid excluding otherwise eligible participants for reasons that are not well-justified. A limitation of this study is that we did not conduct detailed review of every study protocol; thus, we were unable to fully evaluate the appropriateness of all comorbidity exclusions...

Read More, https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771091